Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo C49 English + 你好 (nǐ hǎo) = limitless possibilities. Start learning Mandarin Chinese today—for free, forever. Amedeo C49 is completely free, for life. Next week: +49.

Breast Cancer

Free Subscription Articles published in BMC Cancer Retrieve available abstracts of 350 articles: HTML format

Single Articles

October 2025
1. LIU Y, Ren T, Chen X, He Q, et al
   Comparative efficacy and safety of CDK4/6 inhibitors combined with endocrine therapy in HR+/HR2- patients with advanced or metastatic breast cancer: a systematic review and network meta-analysis.
   BMC Cancer. 2025;25:1535.
   PubMed    
   
   
   
2. TAKADA K, Kashiwagi S, Nishikawa M, Kochi A, et al
   Differences in Sentinel lymph node biopsy outcomes and prognosis between HER2-low and HER2-zero breast cancer.
   BMC Cancer. 2025;25:1518.
   PubMed     Abstract available
   
   
   
3. VARGHESE D, Collins J, Nordstrom B, Miranda M, et al
   Epidemiology and outcomes associated with brain metastases among patients with metastatic breast cancer - a cohort study in US electronic health record data.
   BMC Cancer. 2025;25:1475.
   PubMed     Abstract available
   
   
   
4. HOSSEINI SS, Askari N, Yaghoobi MM
   Combined anti-tumor effects of metformin and azacitidine in breast cancer cells.
   BMC Cancer. 2025;25:1487.
   PubMed     Abstract available
   
   
   
5. AFAYA A, Lee H, Kim SY, Park CG, et al
   Multilevel factors associated with clinical breast examination uptake among women in the Northern Region of Ghana: a cross-sectional survey.
   BMC Cancer. 2025;25:1476.
   PubMed     Abstract available
   
   
   
6. KORANTZIS I, Koumarianou A, Rapti V, Timotheadou E, et al
   Real-world management strategies and clinical outcomes of metastatic HER2-positive breast cancer in Greece in the second-line setting and beyond (the togetHER study).
   BMC Cancer. 2025;25:1473.
   PubMed     Abstract available
   
   
   September 2025
7. AL-TAJ MA
   Sweets consumption and breast cancer risk among women in yemen: a matched case control study.
   BMC Cancer. 2025;25:1495.
   PubMed     Abstract available
   
   
   
8. WYATT LC, Nguyen CH, LeCroy MN, Foster V, et al
   Prevalence of breast, cervical, and colorectal cancer screenings among select New York City populations.
   BMC Cancer. 2025;25:1469.
   PubMed     Abstract available
   
   
   
9. CHEN X, Cheng Z, Li Y, Wu X, et al
   Development and validation of a machine learning model to predict delays in seeking medical care among patients with breast cancer in China.
   BMC Cancer. 2025;25:1442.
   PubMed     Abstract available
   
   
   
10. ZHOU J, Liang B, Su M, Zhang Z, et al
    Long-term exposures to PM(2.5) components increase the breast cancer mortality in the region of Inner Mongolia, China: a retrospective study based on mixture cure model.
    BMC Cancer. 2025;25:1465.
    PubMed     Abstract available
    
    
    
11. DURRANI S, Al-Ghamdi AA, Al-Bugawi A, Al-Khammash A, et al
    Prognostic factors and survival outcome of brain metastases in breast cancer patients: a retrospective analysis.
    BMC Cancer. 2025;25:1455.
    PubMed     Abstract available
    
    
    
12. YAHYAPOUR A, Askari N, Yaghoobi MM
    Combination of hydralazine and all-trans retinoic acid targeting breast cancer cells.
    BMC Cancer. 2025;25:1427.
    PubMed     Abstract available
    
    
    
13. JANG MK, Park S, Jeon JY, Kang MJ, et al
    Correction: Evaluating the effects of a resistance exercise intervention for sarcopenia in patients receiving neoadjuvant chemotherapy for breast cancer: study protocol for a randomized controlled trial.
    BMC Cancer. 2025;25:1422.
    PubMed    
    
    
    August 2025
14. YANG Y, Zhao Y, Yao K, Li W, et al
    The influence of cancer treatments on long-term psychological outcomes and quality of life in breast cancer patients.
    BMC Cancer. 2025;25:1403.
    PubMed     Abstract available
    
    
    
15. KURANT DE, Groha S, Ding Y, German C, et al
    Association between polygenic risk and survival in breast cancer patients.
    BMC Cancer. 2025;25:1393.
    PubMed    
    
    
    
16. LI JD, Deng LL, Luo JY, Mo CH, et al
    The role of collagen type VI alpha 6 chain as a potential tumor suppressor in breast cancer: an immune regulation perspective.
    BMC Cancer. 2025;25:1363.
    PubMed     Abstract available
    
    
    
17. ARAUJO CFM, Nunes LC, Murta-Nascimento C, Bragagnoli AC, et al
    Metformin for the treatment of breast cancer: a scoping review of randomized clinical trials.
    BMC Cancer. 2025;25:1352.
    PubMed     Abstract available
    
    
    
18. WANG Y, Wang L, Yu B, Wen S, et al
    Global, regional, and national burden of male breast cancer and predictions in the next 30 years: a systematic analysis of the global burden of disease study 2021.
    BMC Cancer. 2025;25:1344.
    PubMed     Abstract available
    
    
    
19. LIAN W, Li L, Hong C, Chen D, et al
    Impact of ovarian function suppression on prognosis in premenopausal patients with HR+/HER2 + early-stage breast cancer: a multi-center retrospective study.
    BMC Cancer. 2025;25:1331.
    PubMed     Abstract available
    
    
    
20. SREENATH ND, Pandalanghat S, Kapoor A, Govind R, et al
    A comparative analysis of Palbociclib and Ribociclib in metastatic hormone receptor-positive, HER2-negative breast cancer: a prospective mid term follow-Up study from an Indian cohort.
    BMC Cancer. 2025;25:1337.
    PubMed     Abstract available
    
    
    
21. TAIWO R, Harary PM, Trinh TTH, Granucci M, et al
    Adaptive cohort design and LAT1 expression scale: study protocol for a Phase 2a trial of QBS72S in breast cancer brain metastases.
    BMC Cancer. 2025;25:1316.
    PubMed     Abstract available
    
    
    
22. LI SY, Li YM, Fang YQ, Jin ZY, et al
    Contrast-enhanced ultrasound radiomics model for predicting axillary lymph node metastasis and prognosis in breast cancer: a multicenter study.
    BMC Cancer. 2025;25:1315.
    PubMed     Abstract available
    
    
    
23. QIN JN, Dai WB, Zhang WH, Chen BJ, et al
    Identification of optimal biomarkers associated with distant metastasis in breast cancer using Boruta and Lasso machine learning algorithms.
    BMC Cancer. 2025;25:1311.
    PubMed     Abstract available
    
    
    
24. MARIOSA D, Ponzano M, Grotta A, Lagerros YT, et al
    Dietary non-enzymatic antioxidant capacity and risk of breast cancer: the Swedish National March Cohort.
    BMC Cancer. 2025;25:1310.
    PubMed     Abstract available
    
    
    
25. FU J, Deng S, Zheng W, Zheng C, et al
    Construction of a transfer learning-based depression detection model for female breast cancer patients: text sentiment analysis.
    BMC Cancer. 2025;25:1307.
    PubMed     Abstract available
    
    
    
26. XING B, Gu C, Fu C, Zhang B, et al
    Diagnostic performance of ultrasound S-Detect technology in evaluating BI-RADS-4 breast nodules 20 mm.
    BMC Cancer. 2025;25:1306.
    PubMed     Abstract available
    
    
    
27. LEE J, Ahn HK, Lee KH, Jung KH, et al
    Randomized, phase II trial to evaluate the efficacy and safety of atezolizumab plus capecitabine adjuvant therapy compared to capecitabine monotherapy for triple receptor-negative breast cancer with residual invasive cancer after neoadjuvant chemother
    BMC Cancer. 2025;25:1295.
    PubMed     Abstract available
    
    
    
28. JANG MK, Park S, Jeon JY, Kang MJ, et al
    Evaluating the effects of a resistance exercise intervention for sarcopenia in patients receiving neoadjuvant chemotherapy for breast cancer: study protocol for a randomized controlled trial.
    BMC Cancer. 2025;25:1296.
    PubMed     Abstract available
    
    
    
29. OLSON R, Cua M, Matthews Q, Laing J, et al
    Phase II single vs hypofractionated irradiation for timely access to partial breast radiotherapy (SHIFT-PB).
    BMC Cancer. 2025;25:1285.
    PubMed     Abstract available
    
    
    
30. SAROOSH R, Ahmad N, Israr B, Nazir A, et al
    Association of diabetes mellitus and breast cancer in adult men and women: a cross-sectional survey.
    BMC Cancer. 2025;25:1276.
    PubMed     Abstract available
    
    
    
31. TAFESE AM, Fentie MT, Seifu BL, Asnake AA, et al
    Breast cancer survival rates and determinants in Ethiopia: a systematic review and meta-analysis of longitudinal studies.
    BMC Cancer. 2025;25:1263.
    PubMed     Abstract available
    
    
    
32. AL-MASRI M, Aljalabneh B, AlMasri R, Alayyan O, et al
    Comparative survival analysis of HER2-positive Pregnancy-Associated Breast Cancer (PABC) and non-Pregnancy-Associated breast Cancer (non-PABC) cohorts: a matched control study.
    BMC Cancer. 2025;25:1252.
    PubMed     Abstract available
    
    
    July 2025
33. LUO L, Zhang X, Chen L, Chen Z, et al
    Dual-targeting and steric hindrance resolution in HER2 IHC: a novel approach to improve diagnostic sensitivity.
    BMC Cancer. 2025;25:1231.
    PubMed     Abstract available
    
    
    
34. WANG W, Wu B, Li J, Shang Y, et al
    The application and predictive value of the weight-adjusted-waist index in BC prevalence assessment: a comprehensive statistical and machine learning analysis using NHANES data.
    BMC Cancer. 2025;25:1234.
    PubMed     Abstract available
    
    
    
35. SHARIATMADARI H, Taheri-Kharameh Z, Kamaliuon N, Ghanbari Hashem Abadi BA, et al
    Comparing the effectiveness of gratitude intervention and behavioral activation technique in breast cancer patients: a randomized trial.
    BMC Cancer. 2025;25:1226.
    PubMed     Abstract available
    
    
    
36. SUN Q, Hu J, Ye Y, Ma L, et al
    The effect of smoking on breast cancer screening results in female population: a study in Wu wei, China.
    BMC Cancer. 2025;25:1225.
    PubMed     Abstract available
    
    
    
37. EKDAHL HJELM T, Gebremariam TY, Weldearegay MF, Sori M, et al
    Stage at diagnosis and tumor characteristics among young women and men with breast cancer, in Ethiopia and Sweden, a descriptive cross-sectional study.
    BMC Cancer. 2025;25:1222.
    PubMed     Abstract available
    
    
    
38. CHAI C, Shao K, Shan G, Li P, et al
    Dosimetric study of TrueBeam single-isocenter vs. Halcyon dual-isocenter VMAT radiotherapy plans for postoperative left-sided breast cancer.
    BMC Cancer. 2025;25:1214.
    PubMed     Abstract available
    
    
    
39. ZHOU X, Wang Y, Xu Q, Ao X, et al
    BALs are prognostic biomarkers and correlate with malignant behaviors in breast cancer.
    BMC Cancer. 2025;25:1205.
    PubMed     Abstract available
    
    
    
40. KING J, Fakhouri W, Jarvis R, Badreldin W, et al
    Abemaciclib in combination with endocrine therapy for the treatment of HR-positive/HER2-negative locally advanced/metastatic breast cancer in the UK: an observational study.
    BMC Cancer. 2025;25:1189.
    PubMed     Abstract available
    
    
    
41. NASIR J, Han B, Hu X, Ling H, et al
    Retrospective insights: clinical characteristics and survival in 403 ILC cases from China.
    BMC Cancer. 2025;25:1188.
    PubMed     Abstract available
    
    
    
42. YANG L, Li Y, Zeng T, Long M, et al
    Gene mutation in cancer patients with diabetes: a real-world retrospective cohort study.
    BMC Cancer. 2025;25:1163.
    PubMed     Abstract available
    
    
    
43. WANG S, Liu J, Song L, Zhao H, et al
    Integrative multimodal ultrasound and radiomics for early prediction of neoadjuvant therapy response in breast cancer: a clinical study.
    BMC Cancer. 2025;25:1156.
    PubMed     Abstract available
    
    
    
44. LLEVENES P, Chen A, Lawton M, Rondon-Ortiz AN, et al
    Plasma exosomes in insulin resistant obesity exacerbate progression of triple negative breast cancer.
    BMC Cancer. 2025;25:1089.
    PubMed     Abstract available
    
    
    
45. MOHEBBI A, Asli F, Mohammadzadeh S, Ardakani AA, et al
    Exploring the role of tumor to background parenchymal ratio of the [18F]FLT PET/CT measures in determining response to neoadjuvant chemotherapy in breast cancer: a multicenter study.
    BMC Cancer. 2025;25:1139.
    PubMed     Abstract available
    
    
    
46. OSBORNE A
    Sex-disaggregated analysis of breast cancer prevalence in Sierra Leone.
    BMC Cancer. 2025;25:1022.
    PubMed     Abstract available
    
    
    
47. HENDY A, Ibrahim RK, Darwish A, Al Sabbah S, et al
    Sleep disturbance, cancer-related fatigue, and depression as determinants of quality of life among breast cancer patients undergoing chemotherapy: a cross-sectional study.
    BMC Cancer. 2025;25:1122.
    PubMed     Abstract available
    
    
    
48. DANG C, Wang R, Shi Y, Liu P, et al
    Genetically proxied therapeutic effect of antihypertensive drug use, breast cancer, and ovarian cancer's risk: a drug-target Mendelian randomization study.
    BMC Cancer. 2025;25:1125.
    PubMed     Abstract available
    
    
    
49. GUO Q, Wu P, He J, Zhang G, et al
    Machine learning algorithms predict breast cancer incidence risk: a data-driven retrospective study based on biochemical biomarkers.
    BMC Cancer. 2025;25:1061.
    PubMed     Abstract available
    
    
    
50. LU Z, Yang J, Feng Y, Ming J, et al
    Integrated proteomics and transcriptomics analysis reveals key regulatory genes between ER-positive/PR-positive and ER-positive/PR-negative breast cancer.
    BMC Cancer. 2025;25:1048.
    PubMed     Abstract available
    
    
    
51. CHEANG I, Gue Y, Wu MZ, Huang JY, et al
    Cardiovascular risks associated with adjuvant endocrine therapy in women with breast cancer: a population-based cohort study.
    BMC Cancer. 2025;25:1063.
    PubMed     Abstract available
    
    
    
52. LIAN J, Yao R, Xu Y, Tan L, et al
    Prediction of the 70-gene signature (MammaPrint) high versus low risk by nomograms among axillary lymph node positive (LN+) and negative (LN-) Chinese breast cancer patients, a retrospective study.
    BMC Cancer. 2025;25:1128.
    PubMed     Abstract available
    
    
    
53. WANG C, Xiao D, Zhai C
    Efficacy and safety of small-molecule TKIs in neoadjuvant treatment of HER2-positive breast cancer: a systematic review and network meta-analysis.
    BMC Cancer. 2025;25:1072.
    PubMed     Abstract available
    
    
    
54. SALLAUKA R, Horvat M, Ravnik M, Rashwan H, et al
    Scoping review: (Bio)markers for the prognostication of breast cancer recurrence.
    BMC Cancer. 2025;25:1081.
    PubMed     Abstract available
    
    
    
55. ANWAR E, Amjad A, Zubairi AJ, Ali MM, et al
    De Novo bone metastasis in breast cancer: tumor biology and survival outcomes in a retrospective study from Pakistan.
    BMC Cancer. 2025;25:1074.
    PubMed     Abstract available
    
    
    
56. CIVIL YA, Duvivier KM, Bartels SAL, Velde SV, et al
    Impact of neoadjuvant systemic therapy on surgical and radiotherapy outcomes in patients with early-stage breast cancer: a cross-sectional retrospective single-center study.
    BMC Cancer. 2025;25:1046.
    PubMed     Abstract available
    
    
    
57. DEBELA MB, Gonfa KB, Hussen MM, Zenbaba D, et al
    Breast cancer determinants in low- to upper-middle-income countries: an umbrella review of meta-analyses of observational studies and an urgent call for implementation science.
    BMC Cancer. 2025;25:1096.
    PubMed     Abstract available
    
    
    
58. CAREW JW, Radulescu SC, Zhang L, Ungurean C, et al
    Breast cancer mortality in Romania: trends, regional and rural-urban inequalities, and policy implications.
    BMC Cancer. 2025;25:1038.
    PubMed     Abstract available
    
    
    
59. HAFEEZ A, Shabbir M, Badshah Y, Farooq A, et al
    Association of PRKCQ variants with breast cancer susceptibility and clinicopathological features.
    BMC Cancer. 2025;25:1069.
    PubMed     Abstract available
    
    
    
60. ZENG Y, Liu R, Rong L
    Predictive value of androgen receptor in distant metastasis of triple-negative breast cancer: a retrospective multi-center study.
    BMC Cancer. 2025;25:1115.
    PubMed     Abstract available
    
    
    
61. MARTI-DIAZ R, Sanchez-Del-Campo L, Montenegro MF, Hernandez-Caselles T, et al
    Ex vivo engineering of phagocytic signals in breast cancer cells for a whole tumor cell-based vaccine.
    BMC Cancer. 2025;25:1029.
    PubMed     Abstract available
    
    
    
62. SHIAU JP, Yang CW, Liu W, Yu SY, et al
    Excavatolide C has oxidative-stress-dependent antiproliferative and apoptotic effects against breast cancer cells.
    BMC Cancer. 2025;25:1023.
    PubMed     Abstract available
    
    
    
63. COSTANZO S, Godino L, De Summa S, Marvulli TM, et al
    BRCA cascade counselling and testing in Italy: current position and future directions.
    BMC Cancer. 2025;25:1044.
    PubMed     Abstract available
    
    
    June 2025
64. WANG W, Sun Y, Li J, Bai H, et al
    Global, regional, and national burden of breast cancer in young women from 1990 to 2021: findings from the global burden of disease study 2021.
    BMC Cancer. 2025;25:1015.
    PubMed     Abstract available
    
    
    
65. EBRAHIM NAA, Hussein MA, Sobeih ME, Amin NH, et al
    From biomarker to targeted therapy: investigating trophoblast cell-surface antigen 2 expression in triple-negative breast cancer- insights from the national cancer institute.
    BMC Cancer. 2025;25:1008.
    PubMed     Abstract available
    
    
    
66. EL-JAMMAL M, Saifi O, Bazan J, Zeidan YH, et al
    Radiation therapy in clinically node positive HER2 positive breast cancer after primary systemic therapy and breast conserving surgery: pooled analysis of TRYPHAENA and NeoSphere trials.
    BMC Cancer. 2025;25:996.
    PubMed     Abstract available
    
    
    
67. KARIMI MA, Khadem R, Haraj A, Farahani MA, et al
    The impact of sodium-glucose cotransporter-2 inhibitors on breast cancer and cancer-related mortality: a systematic review and meta-analysis of randomized controlled trials.
    BMC Cancer. 2025;25:991.
    PubMed     Abstract available
    
    
    
68. OSBORNE A, Adnani QES, Ahinkorah BO
    Breast cancer incidence in Indonesia: a sex-disaggregated analysis using WHO health equity assessment toolkit data.
    BMC Cancer. 2025;25:986.
    PubMed     Abstract available
    
    
    
69. LIANG Y, Xu H, Lin J, Tang W, et al
    Multi-modal radiomics model based on four imaging modalities for predicting pathological complete response to neoadjuvant treatment in breast cancer.
    BMC Cancer. 2025;25:985.
    PubMed     Abstract available
    
    
    
70. BREEK K, Abuhalima D, Salameh H, Al-Jabi SW, et al
    Self-reported side effects of breast cancer treatment and its impact on quality of life: a multicenter cross-sectional study in a low- and middle-income country.
    BMC Cancer. 2025;25:975.
    PubMed     Abstract available
    
    
    
71. AL-MATRAFI AR, Bedair KF, Srinivasan S, Palmer C, et al
    Clinical and pharmacogenomic predictors of survival in tamoxifen treated breast cancer female patients: a real-world study.
    BMC Cancer. 2025;25:974.
    PubMed     Abstract available
    
    
    May 2025
72. WANG C, Chen J, Lv X, Yun T, et al
    Ki-67-Playing a key role in breast cancer but difficult to apply precisely in the real world.
    BMC Cancer. 2025;25:962.
    PubMed     Abstract available
    
    
    
73. YANG B, Sun Z, Ouyang Q, Tong Z, et al
    Safety and quality of life of CDK4/6 inhibitors therapy for hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: a multicenter cross-sectional survey in China.
    BMC Cancer. 2025;25:951.
    PubMed     Abstract available
    
    
    
74. SCHANTZ C, Gnangnon FHR, Aboubakar M, Agbodande AK, et al
    Barriers and opportunities related to access to oncology care in Benin: a qualitative study on breast cancer.
    BMC Cancer. 2025;25:947.
    PubMed     Abstract available
    
    
    
75. NOPOUR R
    Prediction of one-year recurrence among breast cancer patients undergone surgery using artificial intelligence-based algorithms: a retrospective study on prognostic factors.
    BMC Cancer. 2025;25:940.
    PubMed     Abstract available
    
    
    
76. HE C, Yu T, Yang L, He L, et al
    Clinical prediction of pathological complete response in breast cancer: a machine learning study.
    BMC Cancer. 2025;25:933.
    PubMed     Abstract available
    
    
    
77. RAJABPOUR MV, Seyyedsalehi MS, Nahvijou A, Nemati S, et al
    Evaluating the breast cancer quality of care indicators in Iran; multicenter study.
    BMC Cancer. 2025;25:925.
    PubMed     Abstract available
    
    
    
78. ARPINO G, De Angelis C, Gerratana L, Lambertini M, et al
    Patient preferences for treatments in hormone receptor-positive/HER2-negative metastatic breast cancer in Italy: a discrete choice experiment study.
    BMC Cancer. 2025;25:920.
    PubMed     Abstract available
    
    
    
79. NDLOVU AK, Kasvosve I, Rantshabeng PS, Sharma K, et al
    Female breast cancer classification using immunohistochemistry biomarkers staining in Botswana.
    BMC Cancer. 2025;25:893.
    PubMed     Abstract available
    
    
    
80. LI H, Zhang CT, Shao HG, Pan L, et al
    Prediction models of breast cancer molecular subtypes based on multimodal ultrasound and clinical features.
    BMC Cancer. 2025;25:886.
    PubMed     Abstract available
    
    
    
81. MOVAHED F, Dehbozorgi M, Goodarzi S, Abianeh FE, et al
    Effect of breast cancer surgery on levels of depression and anxiety: a systematic review and meta-analysis.
    BMC Cancer. 2025;25:889.
    PubMed     Abstract available
    
    
    
82. LU Y, Shi Z, Zhao Q, Bi Z, et al
    Exploring the clinical value of regional nodal irradiation in sentinel lymph node positive breast cancer patients omitting axillary dissection.
    BMC Cancer. 2025;25:866.
    PubMed     Abstract available
    
    
    
83. ZARGARANI N, Kavousi M, Aliasgari E
    A potential new strategy for BC treatment: NPs containing solanine and evaluation of its anticancer and antimetastatic properties.
    BMC Cancer. 2025;25:860.
    PubMed     Abstract available
    
    
    
84. BROWN C, Kang HA, Johnsrud M, Terry J, et al
    Assessing equity of care across metastatic breast cancer treatment junctures: a multi-site retrospective cohort study.
    BMC Cancer. 2025;25:861.
    PubMed     Abstract available
    
    
    
85. KANG Y, Han B, Kong Y, Liu S, et al
    Efficacy and safety of first-line CDK4/6 inhibitors plus AI therapy for patients with HR +/HER2- advanced breast cancer: a network meta-analysis.
    BMC Cancer. 2025;25:843.
    PubMed     Abstract available
    
    
    
86. DE SOUZA MAMEDE VF, Bernabe RAM, Santos TG, da Silva LL, et al
    Risk of sarcopenia in women with breast cancer: a comparative analysis of screening tools.
    BMC Cancer. 2025;25:839.
    PubMed     Abstract available
    
    
    
87. AHMAD S, Zafar I, Shafiq S, Sehar L, et al
    Deep learning-based computational approach for predicting ncRNAs-disease associations in metaplastic breast cancer diagnosis.
    BMC Cancer. 2025;25:830.
    PubMed     Abstract available
    
    
    
88. YANG Y, Liao T, Lin XH, Ouyang R, et al
    Dual-region MRI radiomic analysis indicates increased risk in high-risk breast lesions: bridging intratumoral and peritumoral radiomics for precision decision-making.
    BMC Cancer. 2025;25:828.
    PubMed     Abstract available
    
    
    
89. YILDIRIM S, Basoglu T, Dogan A, Akdag G, et al
    The impact of carboplatin on pathologic complete response and survival based on HER2 low and HER2 zero status in triple negative breast cancer patients receiving neoadjuvant chemotherapy: a multicenter real-world analysis.
    BMC Cancer. 2025;25:833.
    PubMed     Abstract available
    
    
    April 2025
90. KHAN K, Anwar M, Badshah Y, Ashraf NM, et al
    Zapotin mitigates breast cancer progression by targeting PKCepsilon mediated glycolytic pathway regulation.
    BMC Cancer. 2025;25:798.
    PubMed     Abstract available
    
    
    
91. HOLM JB, Bruun JM, Christiansen P, Thomsen RW, et al
    HbA(1c) levels and breast cancer prognosis in women without diabetes.
    BMC Cancer. 2025;25:790.
    PubMed     Abstract available
    
    
    
92. ZHANG L, Li S, Shi J, Guo H, et al
    The LncRNA RMST-miR-4295-ITPR1 axis: a key mechanism in regulating autophagy in triple-negative breast cancer cells.
    BMC Cancer. 2025;25:782.
    PubMed     Abstract available
    
    
    
93. LI Z, Zhao Z, Zhang T, Yang X, et al
    Association between triglyceride-glucose related indicators, genetic risk, and incident breast cancer among postmenopausal women in UK Biobank.
    BMC Cancer. 2025;25:781.
    PubMed     Abstract available
    
    
    
94. ESMAELI M, Dehabadi MD, Khaleghi AA
    Cannabidiol as a novel therapeutic agent in breast cancer: evidence from literature.
    BMC Cancer. 2025;25:772.
    PubMed     Abstract available
    
    
    
95. RAVEENDRAN C, Meloot SS, Yadev IP
    Clinical and biochemical amenorrhea in premenopausal patients with breast cancer treated with chemotherapy - a prospective cohort study.
    BMC Cancer. 2025;25:753.
    PubMed     Abstract available
    
    
    
96. GLORY A, Patocskai E, Wong P
    Breast cancer PAINT: a first-in-human, dose-escalation study to determine the safety of Plasma Adjuvant INtra-operative Treatment in breast cancer patients.
    BMC Cancer. 2025;25:748.
    PubMed     Abstract available
    
    
    
97. ZHANG Y, Wang H, Wang Y, Ma B, et al
    FOXO1 mediates miR-99a-5p/E2F7 to restrain breast cancer cell proliferation and induce apoptosis.
    BMC Cancer. 2025;25:747.
    PubMed     Abstract available
    
    
    
98. GUPTA H, Raghubansi A, Bharat, Sharma K, et al
    Targeting GSK3beta and signaling pathways in breast cancer: role of individual members of miR- 23/24/27 cluster.
    BMC Cancer. 2025;25:737.
    PubMed     Abstract available
    
    
    
99. CASTELLANO I, Rousset S, Casella D, Capella G, et al
    Early detection of triple-negative breast cancer: evidence of a favourable prognostic impact in a comparative analysis of screen-detected versus symptomatic cases.
    BMC Cancer. 2025;25:730.
    PubMed     Abstract available
    
    
    
100. LIAN W, Li L, Chen D, Hong C, et al
     Adjuvant ovarian function suppression in premenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative early breast cancer: a multi-center retrospective study.
     BMC Cancer. 2025;25:723.
     PubMed     Abstract available
     
     
     
101. LIU J, Guan X, Gao S, Quan L, et al
     Novel insight of critical genes involved in breast cancer brain metastasis: evidence from a cross-tissue transcriptome association study and validation through external clinical cohorts.
     BMC Cancer. 2025;25:707.
     PubMed     Abstract available
     
     
     
102. RASHID FA, Anwar W, Kandakurti PK, Al Qawasmeh KHA, et al
     Physical rehabilitation program for cardiorespiratory health and quality of life among breast cancer survivors in UAE: a randomized control trial.
     BMC Cancer. 2025;25:705.
     PubMed     Abstract available
     
     
     
103. SAGDIC MF, Dincer B, Ozaslan C
     De-escalation of axillary surgery in early breast cancer: translating ACOSOG Z0011 study into clinical practice for breast-conserving surgery patients with positive sentinel lymph node biopsy.
     BMC Cancer. 2025;25:706.
     PubMed     Abstract available
     
     
     
104. TANG H, Zhang W, Li X, Zou Q, et al
     Impact of early multidisciplinary team interventions on dietary management behavior in breast cancer patients: a pilot randomized controlled trial.
     BMC Cancer. 2025;25:699.
     PubMed     Abstract available
     
     
     
105. LI Z, Miao H, Bao W, Zhang L, et al
     Development and validation of a nomogram model of lung metastasis in breast cancer based on machine learning algorithm and cytokines.
     BMC Cancer. 2025;25:692.
     PubMed     Abstract available
     
     
     
106. LIN X, Yang H, Cai T, Yang Z, et al
     Polygonum multiflorum Stilbene Glycoside Oligomers induce the ferroptosis of triple negative breast cancer cells.
     BMC Cancer. 2025;25:676.
     PubMed     Abstract available
     
     
     
107. ROUX A, Hervouet L, Di Stefano F, French DP, et al
     Correction: Acceptability of risk-based breast cancer screening among professionals and healthcare providers from 6 countries contributing to the MyPeBS study.
     BMC Cancer. 2025;25:687.
     PubMed    
     
     
     
108. GETU MA, Kaba M, Addissie A, Seife E, et al
     Patients' experiences of cognitive behavioural therapy integrated with activity pacing: a qualitative study.
     BMC Cancer. 2025;25:670.
     PubMed     Abstract available
     
     
     
109. REN W, Yu Y, Wang T, Wang X, et al
     Comprehensive analysis of metabolism-related gene biomarkers reveals their impact on the diagnosis and prognosis of triple-negative breast cancer.
     BMC Cancer. 2025;25:668.
     PubMed     Abstract available
     
     
     
110. BOSSON-AMEDENU S, Ayitey E, Ayiah-Mensah F, Asare L, et al
     Evaluating key predictors of breast cancer through survival: a comparison of AFT frailty models with LASSO, ridge, and elastic net regularization.
     BMC Cancer. 2025;25:665.
     PubMed     Abstract available
     
     
     
111. ZHU W, Fang J, Zhang Y, Chen M, et al
     Validation of in vivo dose using EPID combined with fan-beam CT guidance in post-breast-conserving radiotherapy for early-stage breast cancer.
     BMC Cancer. 2025;25:667.
     PubMed     Abstract available
     
     
     
112. AKHLAQI M, Ghofrani A, Najdi N, Ranjkesh M, et al
     A systematic review and meta-analysis of pregnancy-associated breast cancer incidence rate.
     BMC Cancer. 2025;25:660.
     PubMed     Abstract available
     
     
     
113. TARAPARA B, Shah F
     Role of MRE11 in DNA damage repair pathway dynamics and its diagnostic and prognostic significance in hereditary breast and ovarian cancer.
     BMC Cancer. 2025;25:650.
     PubMed     Abstract available
     
     
     
114. WANG S, Guo J, Xian X, Li M, et al
     Correction: Distinct 5-methylcytosine profiles of LncRNA in breast cancer brain metastasis.
     BMC Cancer. 2025;25:625.
     PubMed    
     
     
     
115. WANG G, Wang S, Song W, Lu C, et al
     Integrating multi-omics data reveals the antitumor role and clinical benefits of gamma-delta T cells in triple-negative breast cancer.
     BMC Cancer. 2025;25:623.
     PubMed     Abstract available
     
     
     
116. ANDO Y, Miyadera H, Bando H, Hashimoto S, et al
     HLA class II-restricted T cell epitopes in public neoantigens of ESR1 and PIK3CA in breast cancer.
     BMC Cancer. 2025;25:610.
     PubMed     Abstract available
     
     
     
117. CARVALHO MM, Bah A, Azrib S, Hiatt RA, et al
     Evaluation of performance indicators of a national breast cancer screening program in Casablanca, Morocco.
     BMC Cancer. 2025;25:612.
     PubMed     Abstract available
     
     
     
118. WU Z, Zhang R, Wu X, Meng X, et al
     Causal association of breast cancer with immune cells: new evidence from bi-directional Mendelian randomization using GWAS summary statistics.
     BMC Cancer. 2025;25:609.
     PubMed     Abstract available
     
     
     
119. NIU R, Wang C, Xie Y, Li S, et al
     Prognostic significance of CD8 + tumor-infiltrating lymphocytes in operable breast cancer: a meta-analysis.
     BMC Cancer. 2025;25:601.
     PubMed     Abstract available
     
     
     
120. SUN Y, Liao Q, Fan Y, Cui C, et al
     DCE-MRI radiomics of primary breast lesions combined with ipsilateral axillary lymph nodes for predicting efficacy of NAT.
     BMC Cancer. 2025;25:589.
     PubMed     Abstract available
     
     
     March 2025
121. AN T, Han H, Xie J, Wang Y, et al
     Enhancing prediction and stratifying risk: machine learning and bayesian-learning models for catheter-related thrombosis in chemotherapy patients.
     BMC Cancer. 2025;25:552.
     PubMed     Abstract available
     
     
     
122. WANG S, Guo J, Xian X, Li M, et al
     Distinct 5-methylcytosine profiles of LncRNA in breast cancer brain metastasis.
     BMC Cancer. 2025;25:557.
     PubMed     Abstract available
     
     
     
123. HANNEMANN J, Oliveira-Ferrer L, Goele AK, Mileva Y, et al
     L-arginine dependence of breast cancer - molecular subtypes matter.
     BMC Cancer. 2025;25:546.
     PubMed     Abstract available
     
     
     
124. CHERAGHALIZADEH H, Adib-Rad H, Pasha H, Chehrazi M, et al
     Effectiveness of face to face and virtual education to promote breast self-examination based on the theory of planned behavior: a randomized controlled trial study.
     BMC Cancer. 2025;25:548.
     PubMed     Abstract available
     
     
     
125. TIAN H, Cai L, Gui Y, Cai Z, et al
     Two-stage augmentation for detecting malignancy of BI-RADS 3 lesions in early breast cancer.
     BMC Cancer. 2025;25:537.
     PubMed     Abstract available
     
     
     
126. YEAN AW, Leong E, King OS, Mohamad Z, et al
     Breast cancer treatment modalities, treatment delays, and survival in Brunei Darussalam.
     BMC Cancer. 2025;25:510.
     PubMed     Abstract available
     
     
     
127. MARBACH D, Brouer-Visser J, Brennan L, Wilson S, et al
     Immune modulation in solid tumors: a phase 1b study of RO6870810 (BET inhibitor) and atezolizumab (PD-L1 inhibitor).
     BMC Cancer. 2025;25:500.
     PubMed     Abstract available
     
     
     
128. BERTOZZI S, Londero AP, Diaz Nanez JA, Di Vora R, et al
     Breast cancer care for the aging population: a focus on age-related disparities in breast cancer treatment.
     BMC Cancer. 2025;25:492.
     PubMed     Abstract available
     
     
     
129. ROUX A, Hervouet L, Stefano FD, French DP, et al
     Acceptability of risk-based breast cancer screening among professionals and healthcare providers from 6 countries contributing to the MyPeBS study.
     BMC Cancer. 2025;25:483.
     PubMed     Abstract available
     
     
     
130. ZHANG N, Shao X, Xu L, Zhu W, et al
     Three-dimensional turbo-spin-echo amide proton transfer-weighted and intravoxel incoherent motion imaging mri for triple-negative breast cancer: a comparison with molecular subtypes and histological grades.
     BMC Cancer. 2025;25:465.
     PubMed     Abstract available
     
     
     
131. QIAN L, Cairong Z, Yongdong L, Quan L, et al
     Prognostic role of STMN1 expression and neoadjuvant therapy efficacy in breast cancer.
     BMC Cancer. 2025;25:453.
     PubMed     Abstract available
     
     
     
132. TERREL-POCCOMO MK, Santillan-Romero G, Quispe-Vicuna C, Ybaseta-Medina J, et al
     Trends in breast cancer mortality in Peru and its geographical areas from 2013 to 2022 and prediction until 2027.
     BMC Cancer. 2025;25:463.
     PubMed     Abstract available
     
     
     
133. BOUZID RS, Bouzid R, Labed H, Serhani I, et al
     Molecular subtyping and target identification in triple negative breast cancer through immunohistochemistry biomarkers.
     BMC Cancer. 2025;25:454.
     PubMed     Abstract available
     
     
     
134. YARMAND S, Atashi N, Kazemi I, Mahmoudi-Zadeh M, et al
     Correction: Association of portfolio diet score with breast cancer risk: insights from a case-control analysis.
     BMC Cancer. 2025;25:448.
     PubMed    
     
     
     
135. RAVINDRANATH KJ, Srinivasan H
     Deciphering the anti-neoplastic potential of Allium ascalonicum in averting the proliferation and epithelial-mesenchymal transition of triple-negative breast cancer through virtual docking and In Vitro approaches.
     BMC Cancer. 2025;25:414.
     PubMed     Abstract available
     
     
     
136. LIU X, Meng Q, Fan W, Ning L, et al
     The effects of intermittent fasting on anthropometric indices, glycemic profile, chemotherapy-related toxicity, and subjective perception in gynecological and breast cancer patients: a systematic review and meta-analysis.
     BMC Cancer. 2025;25:419.
     PubMed     Abstract available
     
     
     
137. XUE C, Yang W, Hu A, He C, et al
     CYP2D6 polymorphisms and endoxifen concentration in Chinese patients with breast cancer.
     BMC Cancer. 2025;25:410.
     PubMed     Abstract available
     
     
     
138. MASELLI-SCHOUERI JH, De Carvalho LEW, De Melo Sette CV, de Abreu LC, et al
     How are we allocating physicians to deal with breast cancer in men and women in Brazil?
     BMC Cancer. 2025;25:392.
     PubMed     Abstract available
     
     
     
139. KANWAL W, Narjis K, Musani S, Nancy F, et al
     Exploring Zanidatamab's efficacy across HER2-positive Malignancies: a narrative review.
     BMC Cancer. 2025;25:382.
     PubMed     Abstract available
     
     
     February 2025
140. ZHANG K, Shen J, Liang Y, Meng X, et al
     Reduction of subclinical acute cardiac injury through DIBH radiotherapy: a single-institution real-world clinical cohort analysis.
     BMC Cancer. 2025;25:373.
     PubMed     Abstract available
     
     
     
141. EGELBERG M, De Marchi T, Schultz N, Tran L, et al
     The potential radiosensitization target PFKFB3 is related to response to radiotherapy in SweBCG91RT: a randomized clinical trial with long-term follow-up.
     BMC Cancer. 2025;25:374.
     PubMed     Abstract available
     
     
     
142. YAN M, Zong Z, Guo W, Li X, et al
     PIK3CA gene mutation status associated with poor prognosis of breast cancer: a retrospective cohort study.
     BMC Cancer. 2025;25:365.
     PubMed     Abstract available
     
     
     
143. HAYES BL, Fleming L, Mahmoud O, Martin RM, et al
     The impact of sleep on breast cancer-specific mortality: a Mendelian randomisation study.
     BMC Cancer. 2025;25:357.
     PubMed     Abstract available
     
     
     
144. WONGMANEERUNG P, Chitapanarux I, Traisathit P, Prasitwattanaseree S, et al
     The association between Ki-67 expression and survival in breast cancer subtypes: a cross-sectional study of Ki-67 cut-point in northern Thailand.
     BMC Cancer. 2025;25:346.
     PubMed     Abstract available
     
     
     
145. LI Y, Song W, Gao P, Guan X, et al
     Global, regional, and national burden of breast, cervical, uterine, and ovarian cancer and their risk factors among women from 1990 to 2021, and projections to 2050: findings from the global burden of disease study 2021.
     BMC Cancer. 2025;25:330.
     PubMed     Abstract available
     
     
     
146. RANTALA J, Seppa K, Eriksson J, Heinavaara S, et al
     Incidence trends of early-onset breast cancer by lifestyle risk factors.
     BMC Cancer. 2025;25:326.
     PubMed     Abstract available
     
     
     
147. XIE L, Kong X, Lin D, Song J, et al
     Application of chest wall perforator flaps in oncoplastic breast-conserving surgery.
     BMC Cancer. 2025;25:328.
     PubMed     Abstract available
     
     
     
148. HATLETVEDT ND, Engebrethsen C, Geisler J, Geisler S, et al
     The impact of functional MDM2-polymorphisms on neutrophil counts in breast cancer patients during neoadjuvant chemotherapy.
     BMC Cancer. 2025;25:308.
     PubMed     Abstract available
     
     
     
149. WENWEN, Jiang Z, Liu J, Liu D, et al
     Integrating ultrasound radiomics and clinicopathological features for machine learning-based survival prediction in patients with nonmetastatic triple-negative breast cancer.
     BMC Cancer. 2025;25:291.
     PubMed     Abstract available
     
     
     
150. WU X, Yuan F, Guo L, Gao D, et al
     Intraductal chemotherapy for triple-negative breast cancer: a pathway to minimally invasive clinical treatment.
     BMC Cancer. 2025;25:285.
     PubMed     Abstract available
     
     
     
151. YARMAND S, Atashi N, Kazemi I, Mahmoudi-Zadeh M, et al
     Association of portfolio diet score with breast cancer risk: insights from a case-control analysis.
     BMC Cancer. 2025;25:274.
     PubMed     Abstract available
     
     
     
152. ZENG Q, Deng Y, Nan J, Zou Z, et al
     Delta dual?region DCE-MRI radiomics from breast masses predicts axillary lymph node response after neoadjuvant therapy for breast cancer.
     BMC Cancer. 2025;25:264.
     PubMed     Abstract available
     
     
     
153. XIE H, Tan T, Li Q, Li T, et al
     Revolutionizing HER-2 assessment: multidimensional radiomics in breast cancer diagnosis.
     BMC Cancer. 2025;25:265.
     PubMed     Abstract available
     
     
     
154. ZANGOURI V, Balaneji SS, Golmoradi R, Kafili E, et al
     Effects of BMI on prognosis, disease-free survival and overall survival of breast cancer.
     BMC Cancer. 2025;25:257.
     PubMed     Abstract available
     
     
     
155. FAMILI-YOUTH EHH, Famili-Youth A, Yang D, Siddique A, et al
     Aberrant expression of collagen type X in solid tumor stroma is associated with EMT, immunosuppressive and pro-metastatic pathways, bone marrow stromal cell signatures, and poor survival prognosis.
     BMC Cancer. 2025;25:247.
     PubMed     Abstract available
     
     
     
156. ZHANG J, Wang Y, Liu Y, Chen H, et al
     Proteomic profiling reveals biological processes and biomarkers involved in the pathogenesis of occult breast cancer.
     BMC Cancer. 2025;25:231.
     PubMed     Abstract available
     
     
     
157. JIAO D, Chen X, Sun X, Lu Z, et al
     A comparative study of mitoxantrone hydrochloride injection and technetium-99 m for tracing axillary sentinel nodes in patients with breast cancer.
     BMC Cancer. 2025;25:209.
     PubMed     Abstract available
     
     
     
158. YAMADA M, Chishima T, Ishikawa T, Narui K, et al
     Breast cancer risk assessment based on a predictive model: evaluation of risk factors among Japanese women.
     BMC Cancer. 2025;25:206.
     PubMed     Abstract available
     
     
     
159. SHEIKHNEZHAD L, Hassankhani H, Sawin EM, Sanaat Z, et al
     What does intimate partner violence mean for women with breast cancer? Experiences of Iranian women.
     BMC Cancer. 2025;25:190.
     PubMed     Abstract available
     
     
     January 2025
160. GETIE M, Mekonnen BA, Seifu D, Mulugeta Y, et al
     Serum cardiac and inflammatory biomarker levels following chemotherapy among female patients with breast cancer attending at Tikur Anbessa Specialized Hospital, Addis Ababa, Ethiopia.
     BMC Cancer. 2025;25:175.
     PubMed     Abstract available
     
     
     
161. GODIVEAU M, Passildas J, Thivat E, Casile M, et al
     Post-therapeutic support and rehabilitation for breast cancer women in complete remission in a thermal resort: study protocol for the PACThe Real-Life conditions observational trial.
     BMC Cancer. 2025;25:174.
     PubMed     Abstract available
     
     
     
162. KAUTZ-FREIMUTH S, Shukri A, Stracke C, Isselhard A, et al
     Factors influencing role preferences in decision-making of healthy women with BRCA1/2 pathogenic variants: subanalysis from a randomised controlled decision coaching trial.
     BMC Cancer. 2025;25:164.
     PubMed     Abstract available
     
     
     
163. WANG Y, Wang R, Lu D, Zeng Y, et al
     Predictive factors for axillary pathological complete response to neoadjuvant therapy in elderly breast cancer patients.
     BMC Cancer. 2025;25:156.
     PubMed     Abstract available
     
     
     
164. BHANGDIA K, Natarajan A, Rudolfson N, Verguet S, et al
     The association of travel distance and other patient characteristics with breast cancer stage at diagnosis and treatment completion at a rural Rwandan cancer facility.
     BMC Cancer. 2025;25:146.
     PubMed     Abstract available
     
     
     
165. PETE R, Pinard C, Sirodot F, Molnar I, et al
     Patient satisfaction with radio-frequency identification (RFID) tag localization compared with wire localization for nonpalpable breast lesions: the RFID trial.
     BMC Cancer. 2025;25:123.
     PubMed     Abstract available
     
     
     
166. JEONG SH, Chun SM, Kim M, Lee YS, et al
     Multimodal treatments and the risk of breast cancer-related lymphedema: insights from a nationally representative cohort in South Korea.
     BMC Cancer. 2025;25:114.
     PubMed     Abstract available
     
     
     
167. NIU S, Sun T, Wang M, Yao L, et al
     Multiple time points for detecting circulating tumor DNA to monitor the response to neoadjuvant therapy in breast cancer: a meta-analysis.
     BMC Cancer. 2025;25:115.
     PubMed     Abstract available
     
     
     
168. BRANDSTETTER LS, Grau A, Heuschmann PU, Muller-Reiter M, et al
     Medication patterns and potentially inappropriate medication in patients with metastatic breast cancer: results of the BRE-BY-MED study.
     BMC Cancer. 2025;25:125.
     PubMed     Abstract available
     
     
     
169. SAFIEDDINE B, Geyer S, Sperlich S, Beller J, et al
     Factors associated with health-related quality of life in women with paid work at breast cancer diagnosis: a German repeated cross-sectional study over the first five years after primary surgery.
     BMC Cancer. 2025;25:98.
     PubMed     Abstract available
     
     
     
170. BECK MH, Brachaczek IA, Gebert P, Blohmer JU, et al
     Incidence of seroma and postoperative complications after breast surgery before and during the Covid-19 pandemic: results from a retrospective multicenter analysis.
     BMC Cancer. 2025;25:91.
     PubMed     Abstract available
     
     
     
171. LIU M, Kilbreath S, Yee J, Beith J, et al
     Motivations and perceptions for physical activity in women living with metastatic breast cancer: a qualitative interview study.
     BMC Cancer. 2025;25:80.
     PubMed     Abstract available
     
     
     
172. BOVELL AAN, Ramaliba T, Goodwin SO, Phillip JC, et al
     Incidence, trends and patterns of female breast, cervical, colorectal and prostate cancers in Antigua and Barbuda, 2017-2021: a retrospective study.
     BMC Cancer. 2025;25:72.
     PubMed     Abstract available
     
     
     
173. CUMMINGS-JOHN C, Bah AJ, Smalle IO, Challe CC, et al
     The patterns of presentation, management and outcomes of breast cancer patients at a tertiary health facility in Sierra Leone.
     BMC Cancer. 2025;25:70.
     PubMed     Abstract available
     
     
     
174. FENG Y, Song Q, Yan L, Li R, et al
     Predicting breast cancer prognosis using PR and PIK3CA biomarkers: a comparative analysis of diagnostic groups.
     BMC Cancer. 2025;25:68.
     PubMed     Abstract available
     
     
     
175. ZHANG F, Wang S, Liu B, Yang W, et al
     Role of immediate injection of methylene blue after fiberoptic ductoscopy in selective ductectomy for patients with pathological nipple discharge.
     BMC Cancer. 2025;25:60.
     PubMed     Abstract available
     
     
     
176. LIU M, Kilbreath S, Yee J, Beith J, et al
     Personal and behavioural factors that influence physical activity in women living with metastatic breast cancer: a qualitative interview study.
     BMC Cancer. 2025;25:48.
     PubMed     Abstract available
     
     
     
177. CHE J, Chen B, Wang X, Liu B, et al
     Correlation analysis of DLG5 and PD-L1 expression in triple-negative breast cancer.
     BMC Cancer. 2025;25:35.
     PubMed     Abstract available
     
     
     
178. XU L, Li P, Hu Y, Xing W, et al
     Cross-cultural adaptation of the simple Chinese version of the medication adherence reasons scale in patients undergoing adjuvant endocrine therapy for breast cancer.
     BMC Cancer. 2025;25:41.
     PubMed     Abstract available
     
     
     
179. WANG Z, Bi Z, Bo H, Xu J, et al
     PRAF2 as a novel biomarker for breast cancer with machine learning and experimentation validation.
     BMC Cancer. 2025;25:32.
     PubMed     Abstract available
     
     
     
180. TANG J, Guo B, Zhong C, Chi J, et al
     Detection of differences in physical symptoms between depressed and undepressed patients with breast cancer: a study using K-medoids clustering.
     BMC Cancer. 2025;25:23.
     PubMed     Abstract available
     
     
     
181. VAYNRUB A, Salazar B, Feng YE, West H, et al
     The breast cancer genetic testing experience: probing the potential utility of an online decision aid in risk perception and decision making.
     BMC Cancer. 2025;25:19.
     PubMed     Abstract available
     
     
     
182. DA SILVA JL, Thuler LCS, de Melo AC
     Breast cancer patterns by age groups in Brazil: insights from population-based registries data.
     BMC Cancer. 2025;25:18.
     PubMed     Abstract available
     
     
     
183. NTEKIM A, Folasire A, Odukoya OA, Sowunmi A, et al
     Pathway to care among adolescents and young adults with breast cancer in Nigeria: a mixed methods study.
     BMC Cancer. 2025;25:11.
     PubMed     Abstract available
     
     
     
184. LONG Z, Qiu Y, Long Z, Jin Z, et al
     Epidemiology of breast cancer in Chinese women from 1990 to 2021: a systematic analysis and comparison with the global burden.
     BMC Cancer. 2025;25:3.
     PubMed     Abstract available
     
     
     
185. LIU J, Zhang J, Li H, Song G, et al
     Anlotinib in combination with metronomic chemotherapy in HER2-negative metastatic breast cancer: an observational and retrospective study.
     BMC Cancer. 2025;25:9.
     PubMed     Abstract available
     
     
     December 2024
186. GLYNOU SP, Sousi S, Cook H, Zargaran A, et al
     A comparison of acellular dermal matrices (ADM) efficacy and complication profile in women undergoing implant-based breast reconstruction: a systematic review and network meta-analysis.
     BMC Cancer. 2024;24:1598.
     PubMed     Abstract available
     
     
     
187. KAHRAMAN S, Hizal M, Demirel BC, Guven DC, et al
     Activity of CDK4/6 inhibitors and parameters affecting survival in elderly patients in age-subgroups: Turkish Oncology Group (TOG) retrospective study.
     BMC Cancer. 2024;24:1592.
     PubMed     Abstract available
     
     
     
188. LEE J, Kang B, Jung JH, Kim HJ, et al
     Feasibility of an indocyanine green-hyaluronic acid mixture (LuminoMark) for targeting suspicious axillary lymph nodes in patients with breast cancer.
     BMC Cancer. 2024;24:1588.
     PubMed     Abstract available
     
     
     
189. ZHANG F, Wang S, Yu C, Jin W, et al
     The association of BMI and subclinical myocardial dysfunction in breast cancer patients after single or dual anti-HER2 targeted therapy.
     BMC Cancer. 2024;24:1585.
     PubMed     Abstract available
     
     
     
190. LIU J, Sun Y, Qi P, Wo Y, et al
     Gene expression profiling for the diagnosis of male breast cancer.
     BMC Cancer. 2024;24:1584.
     PubMed     Abstract available
     
     
     
191. CHEN Y, He J, Song T, Zhang Y, et al
     Comparing supraclavicular surgery with radiotherapy versus radiotherapy alone in breast cancer patients with ipsilateral supraclavicular lymph node metastasis: a two-center retrospective cohort study.
     BMC Cancer. 2024;24:1572.
     PubMed     Abstract available
     
     
     
192. KIRLI BOLUKBAS M, Figen M, Kocak Uzel E
     Cancer awareness across borders: a comparative study of internet search trends for breast and prostate cancer in Europe and Turkey.
     BMC Cancer. 2024;24:1563.
     PubMed     Abstract available
     
     
     
193. SUN H, Liang J, Xue S, Zhang X, et al
     Establishment and clinical application of a prognostic index for inflammatory status in triple-negative breast cancer patients undergoing neoadjuvant therapy using machine learning.
     BMC Cancer. 2024;24:1559.
     PubMed     Abstract available
     
     
     
194. SCHMIDT M, Vernooij R, van Nuland M, Smeijsters E, et al
     Impaired liver function: effect on paclitaxel toxicity, dose modifications and overall survival.
     BMC Cancer. 2024;24:1553.
     PubMed     Abstract available
     
     
     
195. AZIZ M, Ejaz SA, Channar PA, Alkhathami AG, et al
     Identification of dimethyl 2,2'-((methylenebis(2-(2H-benzo[d][1,2,3]triazol-2-yl)-4-(2,4,4-trimethylpentan-2-yl)-6,1phenylene))bis(oxy))diacetate (TAJ4) as antagonist of NEK-Family: a future for potential drug discovery.
     BMC Cancer. 2024;24:1521.
     PubMed     Abstract available
     
     
     
196. ZHANG X, Zhang Y, Du W
     Alleviating role of ketamine in breast cancer cell-induced osteoclastogenesis and tumor bone metastasis-induced bone cancer pain through an SRC/EGR1/CST6 axis.
     BMC Cancer. 2024;24:1535.
     PubMed     Abstract available
     
     
     
197. GNANGNON FHR, Lawani I, Knight SR, Parente A, et al
     Assessing the continuum of care in Sub-Saharan African hospitals performing surgery for breast cancer: a secondary analysis of the GlobalSurg 3 study.
     BMC Cancer. 2024;24:1529.
     PubMed     Abstract available
     
     
     
198. WANG Y, Zhong P, Wang C, Huang W, et al
     Genetic overlap between breast cancer and sarcopenia: exploring the prognostic implications of SLC38A1 gene expression.
     BMC Cancer. 2024;24:1533.
     PubMed     Abstract available
     
     
     
199. EKHOLM A, Wang Y, Vallon-Christersson J, Boissin C, et al
     Prediction of gene expression-based breast cancer proliferation scores from histopathology whole slide images using deep learning.
     BMC Cancer. 2024;24:1510.
     PubMed     Abstract available
     
     
     
200. NOMAN S, Elarusy NME, Rahman HA, Ismail S, et al
     Investigating the effect of the educational intervention based on the Health Belief Model on the knowledge and beliefs of Yemeni teachers in the use of breast cancer screening: a randomized controlled trial study.
     BMC Cancer. 2024;24:1506.
     PubMed     Abstract available
     
     
     
201. BOAITEY GA, Martini R, Stonaker B, Bonsu EO, et al
     Patterns of breast cancer locoregional relapse, metastasis, and subtypes in Ghana.
     BMC Cancer. 2024;24:1485.
     PubMed     Abstract available
     
     
     November 2024
202. RONG RY, Shen YK, Wu SN, Xu SH, et al
     Prediction model for ocular metastasis of breast cancer: machine learning model development and interpretation study.
     BMC Cancer. 2024;24:1472.
     PubMed     Abstract available
     
     
     
203. LI Y, Yang X, Ma L
     Prognostic prediction for HER2-low breast cancer patients using a novel machine learning model.
     BMC Cancer. 2024;24:1474.
     PubMed     Abstract available
     
     
     
204. KVERNROD AB, Rasmussen CH, Pedersen LH, Bojesen SE, et al
     Attitudes towards risk-stratified breast cancer screening in Denmark - a qualitative study.
     BMC Cancer. 2024;24:1453.
     PubMed     Abstract available
     
     
     
205. ZHANG H, Jin J, Li L, Wang L, et al
     Outcome and toxicities of postmastectomy radiotherapy with integral cervicothoracic thermoplastic mask.
     BMC Cancer. 2024;24:1445.
     PubMed     Abstract available
     
     
     
206. MO JL, Li X, Lei L, Peng J, et al
     A machine learning model revealed that exosome small RNAs may participate in the development of breast cancer through the chemokine signaling pathway.
     BMC Cancer. 2024;24:1435.
     PubMed     Abstract available
     
     
     
207. MEHNERT E, Moller FS, Hofbauer C, Weidlich A, et al
     Palliative care of proximal femur metastatic disease and osteolytic lesions: results following surgical and radiation treatment.
     BMC Cancer. 2024;24:1431.
     PubMed     Abstract available
     
     
     
208. QIAN C, Xing Y, Cheng W
     Causal effect between breast cancer and ovarian cancer: a two-sample mendelian randomization study.
     BMC Cancer. 2024;24:1433.
     PubMed     Abstract available
     
     
     
209. MALMSTROM M, Holst-Hansson A, Olsson Moller U
     The complexity of needs and roles of family members during breast cancer rehabilitation: a qualitative study.
     BMC Cancer. 2024;24:1430.
     PubMed     Abstract available
     
     
     
210. SHI S, Ma HY, Sang YZ, Ju YB, et al
     CD147 expression as a clinicopathological and prognostic indicator in breast cancer: a meta-analysis and bioinformatics analysis.
     BMC Cancer. 2024;24:1429.
     PubMed     Abstract available
     
     
     
211. POWLA PP, Medina H, Villamar D, Huard C, et al
     Racial disparities in the frequency and timing of code status orders among women with breast cancer.
     BMC Cancer. 2024;24:1426.
     PubMed     Abstract available
     
     
     
212. SCHUMACHER TJ, Iyer AV, Rumbley J, Ronayne CT, et al
     Exploring the impact of mitochondrial-targeting anthelmintic agents with GLUT1 inhibitor BAY-876 on breast cancer cell metabolism.
     BMC Cancer. 2024;24:1415.
     PubMed     Abstract available
     
     
     
213. GOTINK J, Rosskamp M, Silversmit G, Verdoodt F, et al
     Exploring educational disparities in breast cancer dynamics: a comprehensive analysis of incidence, death within 5 years of diagnosis, and mortality in the Belgian context.
     BMC Cancer. 2024;24:1399.
     PubMed     Abstract available
     
     
     
214. SRIVASTAVA TP, Ajmeriya S, Goel I, Talukdar J, et al
     Prognostic role of Androgen Receptor splice variant 7 (AR-V7) in the pathogenesis of breast cancer.
     BMC Cancer. 2024;24:1398.
     PubMed     Abstract available
     
     
     
215. XU Y, Huang L, Wang J, He J, et al
     Exploring optimal administration timing of pegylated recombinant human granulocyte colony-stimulating factor for chemotherapy-induced neutropenia in early breast cancer treated with pharmorubicin and endoxan: a prospective randomized controlled clinic
     BMC Cancer. 2024;24:1387.
     PubMed     Abstract available
     
     
     
216. YOON SH, Lee S, Kim HS, Song J, et al
     NSDHL contributes to breast cancer stem-like cell maintenance and tumor-initiating capacity through TGF-beta/Smad signaling pathway in MCF-7 tumor spheroid.
     BMC Cancer. 2024;24:1370.
     PubMed     Abstract available
     
     
     
217. BI Z, Cheng WH, Zheng WH, Ren TY, et al
     The optimal timing of breast cancer surgery after COVID-19 infection: an observational study.
     BMC Cancer. 2024;24:1348.
     PubMed     Abstract available
     
     
     October 2024
218. WANG Z, You P, Yang Z, Xiao H, et al
     PD-1/PD-L1 immune checkpoint inhibitors in the treatment of unresectable locally advanced or metastatic triple negative breast cancer: a meta-analysis on their efficacy and safety.
     BMC Cancer. 2024;24:1339.
     PubMed     Abstract available
     
     
     
219. KATAOKA N, Hata T, Hosomi K, Hirata A, et al
     Predictors of abemaciclib discontinuation in patients with breast cancer: a multicenter retrospective cohort study.
     BMC Cancer. 2024;24:1335.
     PubMed     Abstract available
     
     
     
220. ONER I, Turkel A, Inci BK, Tolunay PK, et al
     Impact of the CPS-EG score as a new prognostic biomarker in triple-negative breast cancer patients who received neoadjuvant chemotherapy.
     BMC Cancer. 2024;24:1338.
     PubMed     Abstract available
     
     
     
221. GARCIA-HERNANDEZ AP, Corona DN, Carlos-Reyes A, Sierra-Martinez M, et al
     The lncRNA AFAP1-AS1 is upregulated in metastatic triple-negative breast tumors and controls hypoxia-activated vasculogenic mimicry and angiogenesis.
     BMC Cancer. 2024;24:1332.
     PubMed     Abstract available
     
     
     
222. NEVIERE Z, Blanc-Fournier C, Guizard AV, Elie N, et al
     Potential of PSMA for breast cancer in nuclear medicine: digital quantitative immunohistochemical analysis and implications for a theranostic approach.
     BMC Cancer. 2024;24:1328.
     PubMed     Abstract available
     
     
     
223. JIAO S, Wang Y, Ma J, Shen J, et al
     Interobserver variability of clinical target volume delineation in patients undergoing breast-conserving surgery without surgical clips: a pilot study on preoperative magnetic resonance simulation.
     BMC Cancer. 2024;24:1321.
     PubMed     Abstract available
     
     
     
224. MSAMI K, Nyamle N, Ruwaichi T, Chuwa H, et al
     Strengthening uptake of breast cancer screening services in Tanzania; re-visiting the breast cancer screening messages.
     BMC Cancer. 2024;24:1312.
     PubMed     Abstract available
     
     
     
225. YANG L, Ding H, Gao X, Xu Y, et al
     Can we skip invasive biopsy of sentinel lymph nodes? A preliminary investigation to predict sentinel lymph node status using PET/CT-based radiomics.
     BMC Cancer. 2024;24:1316.
     PubMed     Abstract available
     
     
     
226. SANTOS TG, da Silva LL, Bernabe RAM, Albergaria BH, et al
     Anthropometric equation has sufficient diagnostic capacity to identify sarcopenia in women with breast cancer.
     BMC Cancer. 2024;24:1310.
     PubMed     Abstract available
     
     
     
227. SEN GA, Aydin E, Guliyev M, Oztas NS, et al
     The impact of HER2-low status on pathological complete response and disease-free survival in early-stage breast cancer.
     BMC Cancer. 2024;24:1311.
     PubMed     Abstract available
     
     
     
228. HACHACHE R, Yahyaouy A, Riffi J, Tairi H, et al
     Advancing personalized oncology: a systematic review on the integration of artificial intelligence in monitoring neoadjuvant treatment for breast cancer patients.
     BMC Cancer. 2024;24:1300.
     PubMed     Abstract available
     
     
     
229. BATCHELOR S, Lunnay B, Macdonald S, Ward PR, et al
     How social class shapes breast cancer risk perspectives and prevention practices of Australian midlife women: a qualitative study using the concept of 'breast cancer candidacy'.
     BMC Cancer. 2024;24:1295.
     PubMed     Abstract available
     
     
     
230. CUI M, Fu J, Li Q
     Comparison of neoadjuvant single-agent treatment and dual-HER2 blockade for breast-conserving surgery conversion in HER2-positive breast cancer: a meta-analysis.
     BMC Cancer. 2024;24:1293.
     PubMed     Abstract available
     
     
     
231. LIU J, He M, Jiang M, Zhou S, et al
     Pyrotinib combined with metronomic etoposide in heavily pretreated HER2-positive metastatic breast cancer: a single-arm, phase II study.
     BMC Cancer. 2024;24:1290.
     PubMed     Abstract available
     
     
     
232. ZIEGLER P, Hartkopf AD, Wallwiener M, Haberle L, et al
     The impact of physical activity on progression-free and overall survival in metastatic breast cancer based on molecular subtype.
     BMC Cancer. 2024;24:1284.
     PubMed     Abstract available
     
     
     
233. CHEN W, Pang L, Jin X, Chen H, et al
     Targeted axillary dissection using carbon marking for patients with node-positive breast cancer following neoadjuvant therapy (TADCOM): study protocol for a prospective, multicenter, randomized controlled trial.
     BMC Cancer. 2024;24:1276.
     PubMed     Abstract available
     
     
     
234. WANG L, Zhen M, Liao L, Li H, et al
     Effects of dietary habits and catheterization type on breast cancer-related lymphedema: a retrospective cohort study.
     BMC Cancer. 2024;24:1264.
     PubMed     Abstract available
     
     
     
235. WANG Y, Xu H, Sa Q, Li L, et al
     Development of graded prognostic assessment for breast Cancer brain metastasis incorporating extracranial metastatic features: a retrospective analysis of 284 patients.
     BMC Cancer. 2024;24:1262.
     PubMed     Abstract available
     
     
     
236. ZHAO Y, He M, Cui L, Zhang M, et al
     Systematic screening of protein-coding gene expression identified VWF as a potential key regulator in anthracycline-based chemotherapy-exacerbated metastasis of breast cancer.
     BMC Cancer. 2024;24:1243.
     PubMed     Abstract available
     
     
     
237. LI Z, Jian C, Li Y, Pan Z, et al
     Clinical benefits of deep inspiration breath-hold in postoperative radiotherapy for right-sided breast cancer: a meta-analysis.
     BMC Cancer. 2024;24:1238.
     PubMed     Abstract available
     
     
     
238. REN K, Wang S, Ye T, Zhu Z, et al
     Efficacy and safety of Anlotinib based neoadjuvant chemotherapy for locally advanced triple negative breast cancer (TNBC).
     BMC Cancer. 2024;24:1237.
     PubMed     Abstract available
     
     
     
239. NOURI M, Mansouri F, Jafari F, Ranjbar Zahedani M, et al
     Association between processed and ultra-processed food intake and the risk of breast cancer: a case-control study.
     BMC Cancer. 2024;24:1234.
     PubMed     Abstract available
     
     
     
240. DO TM, Nguyen QHN, Le NHD, Nguyen HD, et al
     Association between dietary factors and breast cancer risk: a matched case-control study in Vietnam.
     BMC Cancer. 2024;24:1224.
     PubMed     Abstract available
     
     
     
241. MA H, Shi L, Zheng J, Zeng L, et al
     Advanced machine learning unveils CD8 + T cell genetic markers enhancing prognosis and immunotherapy efficacy in breast cancer.
     BMC Cancer. 2024;24:1222.
     PubMed     Abstract available
     
     
     September 2024
242. BAHARUN NB, Adam A, Zailani MAH, Rajpoot NM, et al
     Automated scoring methods for quantitative interpretation of Tumour infiltrating lymphocytes (TILs) in breast cancer: a systematic review.
     BMC Cancer. 2024;24:1202.
     PubMed     Abstract available
     
     
     
243. XIONG Z, Liu K, Liu S, Feng J, et al
     Precision HER2: a comprehensive AI system for accurate and consistent evaluation of HER2 expression in invasive breast Cancer.
     BMC Cancer. 2024;24:1204.
     PubMed     Abstract available
     
     
     
244. WANG D, Xie D, Meng S, Mi J, et al
     Role and molecular mechanisms of HuangQiSiJunZi decoction for treating triple-negative breast cancer as explored via network pharmacology and bioinformatics analyses.
     BMC Cancer. 2024;24:1217.
     PubMed     Abstract available
     
     
     
245. NI M, Zhou L, Lu Y, Guo D, et al
     Eribulin plus carboplatin combination for HER2-negative metastatic breast cancer: a multicenter, real-world cohort study.
     BMC Cancer. 2024;24:1214.
     PubMed     Abstract available
     
     
     
246. RAN R, Zhao S, Zhou Y, Hang X, et al
     Clinicopathological characteristics, treatment patterns and outcomes in patients with HER2-positive breast cancer based on hormone receptor status: a retrospective study.
     BMC Cancer. 2024;24:1216.
     PubMed     Abstract available
     
     
     
247. REZAIE-CHAMANI S, Lamyian M, Ahmadi F, Montazeri A, et al
     I trust doctors and midwives: exploring breast cancer literacy among women referring to the health centers in Iran.
     BMC Cancer. 2024;24:1201.
     PubMed     Abstract available
     
     
     
248. OGUNMODEDE EO, Ajala DE, Aluko JO, Anokwuru RA, et al
     Promoting breast health among female adolescents: a comparative analysis of the effects of two didactic tools on knowledge and practice regarding breast self-examination in Southwest Nigeria.
     BMC Cancer. 2024;24:1183.
     PubMed     Abstract available
     
     
     
249. COOK HI, Glynou SP, Sousi S, Zargaran D, et al
     Does the use of Acellular Dermal Matrices (ADM) in women undergoing pre-pectoral implant-based breast reconstruction increase operative success versus non-use of ADM in the same setting? A systematic review.
     BMC Cancer. 2024;24:1186.
     PubMed     Abstract available
     
     
     
250. HU S, Tey SK, Kwong A
     Adipogenesis biomarkers as the independent predictive factors for breast cancer recurrence: a systematic review and meta-analysis.
     BMC Cancer. 2024;24:1181.
     PubMed     Abstract available
     
     
     
251. WU F, Li N, Wu X, Chen M, et al
     EZH2 mutation is associated with the development of visceral metastasis by enhancing proliferation and invasion and inhibiting apoptosis in breast cancer cells.
     BMC Cancer. 2024;24:1166.
     PubMed     Abstract available
     
     
     
252. TANG M, Rong Y, Li X, Pan H, et al
     Anoikis-related genes in breast cancer patients: reliable biomarker of prognosis.
     BMC Cancer. 2024;24:1163.
     PubMed     Abstract available
     
     
     
253. KOBAYASHI T, Nishimura M, Hosonaga M, Kizawa R, et al
     Absolute lymphocyte count predicts efficacy of palbociclib in patients with metastatic luminal breast cancer.
     BMC Cancer. 2024;24:1156.
     PubMed     Abstract available
     
     
     
254. CHENG Z, Xu H, Wang X, Teng T, et al
     A causal relationship between bone mineral density and breast cancer risk: a mendelian randomization study based on east Asian population.
     BMC Cancer. 2024;24:1148.
     PubMed     Abstract available
     
     
     
255. ZHANG Q, Wang Z, Yao W, Wang S, et al
     A randomized, multicenter phase III Study of once-per-cycle administration of efbemalenograstim alfa (F-627), a novel long-acting rhG-CSF, for prophylaxis of chemotherapy-induced neutropenia in patients with breast cancer.
     BMC Cancer. 2024;24:1143.
     PubMed     Abstract available
     
     
     
256. CANCILLA MA, Nemati D, Halsey D, Shah N, et al
     Exercise as part of survivorship care in metastatic breast cancer: protocol for the randomized EMBody trial.
     BMC Cancer. 2024;24:1137.
     PubMed     Abstract available
     
     
     
257. YU X, Yu Y, Huang X, Jiang Z, et al
     Unraveling the causal links and novel molecular classification of Crohn's disease in breast Cancer: a two-sample mendelian randomization and transcriptome analysis with prognostic modeling.
     BMC Cancer. 2024;24:1134.
     PubMed     Abstract available
     
     
     
258. BALLE JK, Vetter M, Kenea TW, Eber-Schulz P, et al
     PAM50 breast cancer subtypes and survival of patients in rural Ethiopia without adjuvant treatment: a prospective observational study.
     BMC Cancer. 2024;24:1127.
     PubMed     Abstract available
     
     
     
259. DESWAL B, Bagchi U, Santra MK, Garg M, et al
     Inhibition of STAT3 by 2-Methoxyestradiol suppresses M2 polarization and protumoral functions of macrophages in breast cancer.
     BMC Cancer. 2024;24:1129.
     PubMed     Abstract available
     
     
     
260. LI H, Xu Y, Xu R, Du W, et al
     The role of HGH1 in breast cancer prognosis: a study on immune response and cell cycle.
     BMC Cancer. 2024;24:1122.
     PubMed     Abstract available
     
     
     
261. KELLEY-JONES C, Scott SE, Waller J
     Acceptability of de-intensified screening for women at low risk of breast cancer: a randomised online experimental survey.
     BMC Cancer. 2024;24:1111.
     PubMed     Abstract available
     
     
     
262. FASSIER JB, Guittard L, Fervers B, Rouat S, et al
     Using intervention mapping to facilitate and sustain return-to work after breast cancer: protocol for the FASTRACS multicentre randomized controlled trial.
     BMC Cancer. 2024;24:1107.
     PubMed     Abstract available
     
     
     
263. DANDENA FG, Teklewold BT, Darebo TD, Suga YD, et al
     Epidemiology and clinical characteristics of breast cancer in Ethiopia: a systematic review.
     BMC Cancer. 2024;24:1102.
     PubMed     Abstract available
     
     
     
264. XIE X, Fang Y, He L, Chen Z, et al
     Individualized prediction of non-sentinel lymph node metastasis in Chinese breast cancer patients with >/= 3 positive sentinel lymph nodes based on machine-learning algorithms.
     BMC Cancer. 2024;24:1090.
     PubMed     Abstract available
     
     
     August 2024
265. LIN TE, Wong AW, Cheong DC, Kuo WL, et al
     Strategically shifting paradigms: the new era of DIEP flaps with minimally invasive mastectomy: a retrospective cross-sectional study.
     BMC Cancer. 2024;24:1072.
     PubMed     Abstract available
     
     
     
266. SONG MY, Zhao L, Huang WJ, Cui MM, et al
     Preoperative platelet distribution width predicts bone metastasis in patients with breast cancer.
     BMC Cancer. 2024;24:1066.
     PubMed     Abstract available
     
     
     
267. TANG W, Gao Y, Hong S, Wang S, et al
     GFPT1 accelerates immune escape in breast cancer by modifying PD-L1 via O-glycosylation.
     BMC Cancer. 2024;24:1071.
     PubMed     Abstract available
     
     
     
268. WANG L, Hong R, Shi S, Wang S, et al
     The prognostic significance of circulating tumor cell enumeration and HER2 expression by a novel automated microfluidic system in metastatic breast cancer.
     BMC Cancer. 2024;24:1067.
     PubMed     Abstract available
     
     
     
269. GAO X, Pan T, Gao Y, Zhu W, et al
     Acetylation of PGK1 at lysine 323 promotes glycolysis, cell proliferation, and metastasis in luminal A breast cancer cells.
     BMC Cancer. 2024;24:1054.
     PubMed     Abstract available
     
     
     
270. ZHANG J, Sun H, Gao S, Kang Y, et al
     Prediction of disease-free survival using strain elastography and diffuse optical tomography in patients with T1 breast cancer: a 10-year follow-up study.
     BMC Cancer. 2024;24:1057.
     PubMed     Abstract available
     
     
     
271. LUO C, Yu K, Luo X, Lian T, et al
     CDK4/6 inhibitors plus endocrine therapy vs. placebo plus endocrine therapy for HR+/HER2- advanced breast cancer: a phase III RCTs based meta-analysis.
     BMC Cancer. 2024;24:1031.
     PubMed     Abstract available
     
     
     
272. CHEN JH, Addanki S, Roy D, Bassett R, et al
     Monitoring response to neoadjuvant chemotherapy in triple negative breast cancer using circulating tumor DNA.
     BMC Cancer. 2024;24:1016.
     PubMed     Abstract available
     
     
     
273. BEKELE K, Nugusu F, Beressa G, Hollis T, et al
     Proportion of early-stage breast cancer at diagnosis in Ethiopia: a systematic review and meta-analysis.
     BMC Cancer. 2024;24:1017.
     PubMed     Abstract available
     
     
     
274. DAJSAKDIPON T, Susiriwatananont T, Wongkraisri C, Ithimakin S, et al
     Comparative effectiveness analysis of survival with first-line palbociclib or ribociclib plus AI in HR + /HER2- advanced breast cancer (CEPRA study): preliminary analysis of real-world data from Thailand.
     BMC Cancer. 2024;24:1018.
     PubMed     Abstract available
     
     
     
275. HU L, Gu Y, Xu W, Wang C, et al
     Association of clinicopathologic and sonographic features with stromal tumor-infiltrating lymphocytes in triple-negative breast cancer.
     BMC Cancer. 2024;24:997.
     PubMed     Abstract available
     
     
     
276. AHMADIRAD H, Norouzzadeh M, Teymoori F, Jahromi MK, et al
     The predictive role of the total potassium intake and odds of breast cancer: a case-control study.
     BMC Cancer. 2024;24:995.
     PubMed     Abstract available
     
     
     
277. KAWAMOTO Y, Yamai T, Ikezawa K, Seiki Y, et al
     Clinical significance of germline breast cancer susceptibility gene (gBRCA) testing and olaparib as maintenance therapy for patients with pancreatic cancer.
     BMC Cancer. 2024;24:1000.
     PubMed     Abstract available
     
     
     
278. ELZOHERY YHAM, Radwan AH, Gareer SWY, Mamdouh MM, et al
     Micropapillary breast carcinoma in comparison with invasive duct carcinoma. Does it have an aggressive clinical presentation and an unfavorable prognosis?
     BMC Cancer. 2024;24:992.
     PubMed     Abstract available
     
     
     
279. LI K, Chai D, Ren S, Lian X, et al
     beta2-microglobulin induced apoptosis of tumor cells via the ERK signaling pathway by directly interacting with HFE in HER2-overexpressing breast cancer.
     BMC Cancer. 2024;24:991.
     PubMed     Abstract available
     
     
     
280. LIN W, Gu C, Chen Z, Xue S, et al
     Exploring the relationship between gut microbiota and breast cancer risk in European and East Asian populations using Mendelian randomization.
     BMC Cancer. 2024;24:970.
     PubMed     Abstract available
     
     
     
281. WOJCIK KM, Caswell-Jin JL, Wilson OWA, Schechter C, et al
     The population-level effects of omitting chemotherapy guided by a 21-gene expression assay in node-positive breast cancer: a simulation modeling study.
     BMC Cancer. 2024;24:975.
     PubMed     Abstract available
     
     
     
282. HEMATI M, Rivaz M, Khademian Z
     Lymphedema self-management mobile application with nurse support for post breast cancer surgery survivors: description of the design process and prototype evaluation.
     BMC Cancer. 2024;24:973.
     PubMed     Abstract available
     
     
     
283. LEE TF, Chang CH, Chi CH, Liu YH, et al
     Utilizing radiomics and dosiomics with AI for precision prediction of radiation dermatitis in breast cancer patients.
     BMC Cancer. 2024;24:965.
     PubMed     Abstract available
     
     
     July 2024
284. WAN LW, Zhang C, Zhang YL, Lin F, et al
     Prognostic significance of the novel immunonutritional marker of cholesterol-to-lymphocyte ratio in patients with non-metastatic breast cancer.
     BMC Cancer. 2024;24:914.
     PubMed     Abstract available
     
     
     
285. HU ZY, Liu B, Xie N, Yang X, et al
     The treatment pattern of advanced HR-positive and HER2-negative breast cancer in central southern China: a hospital-based cross-sectional study.
     BMC Cancer. 2024;24:915.
     PubMed     Abstract available
     
     
     
286. ANABA EA, Alor SK, Badzi CD, Mbuwir CB, et al
     Drivers of breast cancer and cervical cancer screening among women of reproductive age: insights from the Ghana Demographic and Health Survey.
     BMC Cancer. 2024;24:920.
     PubMed     Abstract available
     
     
     
287. WANG X, Nie L, Zhu Q, Zuo Z, et al
     Artificial intelligence assisted ultrasound for the non-invasive prediction of axillary lymph node metastasis in breast cancer.
     BMC Cancer. 2024;24:910.
     PubMed     Abstract available
     
     
     
288. RAEI M, Heydari K, Tabarestani M, Razavi A, et al
     Diagnostic accuracy of ESR1 mutation detection by cell-free DNA in breast cancer: a systematic review and meta-analysis of diagnostic test accuracy.
     BMC Cancer. 2024;24:908.
     PubMed     Abstract available
     
     
     
289. LI X, Cheng K, Shang MD, Yang Y, et al
     MARCH1 negatively regulates TBK1-mTOR signaling pathway by ubiquitinating TBK1.
     BMC Cancer. 2024;24:902.
     PubMed     Abstract available
     
     
     
290. YIALLOUROU A, Pantavou K, Markozannes G, Pilavas A, et al
     Non-genetic factors and breast cancer: an umbrella review of meta-analyses.
     BMC Cancer. 2024;24:903.
     PubMed     Abstract available
     
     
     
291. JIANG M, Chai Y, Liu J, He M, et al
     Neoadjuvant inetetamab and pertuzumab with taxanes and carboplatin (TCbIP) In locally advanced HER2-positive breast cancer: a prospective cohort study with propensity-matched analysis.
     BMC Cancer. 2024;24:877.
     PubMed     Abstract available
     
     
     
292. TANG H, Zhang W, Shen H, Tang H, et al
     A protocol for a multidisciplinary early intervention during chemotherapy to improve dietary management behavior in breast cancer patients: a two-arm, single-center randomized controlled trial.
     BMC Cancer. 2024;24:859.
     PubMed     Abstract available
     
     
     
293. SOHRABEI S, Moghaddasi H, Hosseini A, Ehsanzadeh SJ, et al
     Investigating the effects of artificial intelligence on the personalization of breast cancer management: a systematic study.
     BMC Cancer. 2024;24:852.
     PubMed     Abstract available
     
     
     
294. CHRISTINE D, Christian SF, Ricarda K, Christine K, et al
     Risk factors for residual fibroglandular breast tissue following a mastectomy - an overview and retrospective cohort study.
     BMC Cancer. 2024;24:856.
     PubMed     Abstract available
     
     
     
295. JIA L, Peng J, Sun N, Chen H, et al
     Effect of PR status on the prognosis of advanced ER-high HER2-negative breast cancer patients receiving CDK4/6 inhibitor combined with endocrine as first-line therapy.
     BMC Cancer. 2024;24:850.
     PubMed     Abstract available
     
     
     
296. DAMTIE Z, Cherie N, Agidew MM
     Breast cancer preventive practices and associated factors among reproductive age women in Wadila District, North East Ethiopia: community based cross-sectional study.
     BMC Cancer. 2024;24:843.
     PubMed     Abstract available
     
     
     
297. POMEY MP, Iliescu Nelea M, Vialaron C, Normandin L, et al
     The black box of the relationship between breast cancer patients and accompanying patients: the accompanied patients' point of view.
     BMC Cancer. 2024;24:822.
     PubMed     Abstract available
     
     
     
298. PIAO YJ, Kim HS, Kim H, Shen J, et al
     SerpinB2 deficiency is associated with delayed mammary tumor development and decreased pro-tumorigenic macrophage polarization.
     BMC Cancer. 2024;24:792.
     PubMed     Abstract available
     
     
     
299. PENG J, Lin Y, Sheng X, Yuan C, et al
     Serum miRNA-1 may serve as a promising noninvasive biomarker for predicting treatment response in breast cancer patients receiving neoadjuvant chemotherapy.
     BMC Cancer. 2024;24:789.
     PubMed     Abstract available
     
     
     
300. MRABTI H, Sauvaget C, Bendahhou K, Selmouni F, et al
     Breast cancer treatment and its impact on survival in Morocco: a study over a decade.
     BMC Cancer. 2024;24:786.
     PubMed     Abstract available
     
     
     June 2024
301. OZORIO DUTRA SV, Schwab L, Coury J, Ji M, et al
     Process evaluation protocol plan for a home-based physical activity intervention versus educational intervention for persistent taxane-induced peripheral neuropathy (B-HAPI study): a randomized controlled trial.
     BMC Cancer. 2024;24:777.
     PubMed     Abstract available
     
     
     
302. BOHANSKE MS, Momenzadeh K, van der Zwaal P, Hoogwater FJH, et al
     Computed tomography-based structural rigidity analysis can assess tumor- and treatment-induced changes in rat bones with metastatic lesions.
     BMC Cancer. 2024;24:767.
     PubMed     Abstract available
     
     
     
303. MASHAYEKH-AMIRI S, Jafarabadi MA, Hosseinzadeh M, Kanani ES, et al
     Measurement properties of the Iranian version of the breast cancer perception scale (BCPS) according to the COSMIN checklist.
     BMC Cancer. 2024;24:743.
     PubMed     Abstract available
     
     
     
304. CANINO F, Barbolini M, De Giorgi U, Fontana T, et al
     Safety and efficacy analysis of neoadjuvant pertuzumab, trastuzumab and standard chemotherapy for HER2-positive early breast cancer: real-world data from NeoPowER study.
     BMC Cancer. 2024;24:735.
     PubMed     Abstract available
     
     
     
305. JORIS S, Giron P, Olsen C, Seneca S, et al
     Identification of RAD17 as a candidate cancer predisposition gene in families with histories of pancreatic and breast cancers.
     BMC Cancer. 2024;24:723.
     PubMed     Abstract available
     
     
     
306. XU C, Sun L, Wang H, Sun J, et al
     Identifying the mechanism of polysaccharopeptide against breast cancer based on network pharmacology and experimental verification.
     BMC Cancer. 2024;24:726.
     PubMed     Abstract available
     
     
     
307. KANG Z, Jin Y, Yu H, Li S, et al
     Relative efficacy of antibody-drug conjugates and other anti-HER2 treatments on survival in HER2-positive advanced breast cancer: a systematic review and meta-analysis.
     BMC Cancer. 2024;24:708.
     PubMed     Abstract available
     
     
     
308. LI Y, Han D, Shen C
     Prediction of the axillary lymph-node metastatic burden of breast cancer by (18)F-FDG PET/CT-based radiomics.
     BMC Cancer. 2024;24:704.
     PubMed     Abstract available
     
     
     
309. XU JX, Zhu QL, Bi YM, Peng YC, et al
     New evidence: Metformin unsuitable as routine adjuvant for breast cancer: a drug-target mendelian randomization analysis.
     BMC Cancer. 2024;24:691.
     PubMed     Abstract available
     
     
     
310. YE J, Ying J, Chen H, Wu Z, et al
     PPIH acts as a potential predictive biomarker for patients with common solid tumors.
     BMC Cancer. 2024;24:681.
     PubMed     Abstract available
     
     
     May 2024
311. AZIZ MA, Chowdhury S, Jafrin S, Barek MA, et al
     Genetic association of Interleukin-17A polymorphism in Bangladeshi patients with breast and cervical cancer: a case-control study with functional analysis.
     BMC Cancer. 2024;24:660.
     PubMed     Abstract available
     
     
     
312. YU S, Yue Z, Liu Q
     Pectinose induces cell cycle arrest in luminal A and triple-negative breast cancer cells by promoting autophagy through activation of the p38 MAPK signaling pathway.
     BMC Cancer. 2024;24:639.
     PubMed     Abstract available
     
     
     
313. KUEMMEL S, Harper-Wynne C, Park YH, Franke F, et al
     heredERA Breast Cancer: a phase III, randomized, open-label study evaluating the efficacy and safety of giredestrant plus the fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection in patients with previously untreated HER2-po
     BMC Cancer. 2024;24:641.
     PubMed     Abstract available
     
     
     
314. LAMBERT V, Kane S, Howidi B, Nguyen BN, et al
     Systematic literature review of real-world evidence for treatments in HR+/HER2- second-line LABC/mBC after first-line treatment with CDK4/6i.
     BMC Cancer. 2024;24:631.
     PubMed     Abstract available
     
     
     
315. ZHENG M, Wu L, Xiao R, Cai J, et al
     Fbxo45 facilitates the malignant progression of breast cancer by targeting Bim for ubiquitination and degradation.
     BMC Cancer. 2024;24:619.
     PubMed     Abstract available
     
     
     
316. WANG Q, Chen H, Yang Q, Qiu J, et al
     Awareness and associated factors of venous thromboembolism in breast cancer surgical patients: a cross-sectional study.
     BMC Cancer. 2024;24:610.
     PubMed     Abstract available
     
     
     
317. EL HABRE R, Aoun R, Tahtouh R, Hilal G, et al
     All-trans-retinoic acid modulates glycolysis via H19 and telomerase: the role of mir-let-7a in estrogen receptor-positive breast cancer cells.
     BMC Cancer. 2024;24:615.
     PubMed     Abstract available
     
     
     
318. BOUTRUS RR, Abdelazim YA, Mohammed T, Bayomy M, et al
     The impact of loco-regional treatment modality on the outcomes in breast cancer patients younger than forty years of age.
     BMC Cancer. 2024;24:599.
     PubMed     Abstract available
     
     
     
319. HAUNER D, Mang A, Donik L, Schederecker F, et al
     Dietary supplement intake in women with breast cancer before and after diagnosis: results from the SUCCESS C trial.
     BMC Cancer. 2024;24:591.
     PubMed     Abstract available
     
     
     
320. SAHU RK, Tandon S, Singh S, Das BC, et al
     Methyl CpG binding protein MBD2 has a regulatory role on the BRCA1 gene expression and its modulation by resveratrol in ER+, PR+ & triple-negative breast cancer cells.
     BMC Cancer. 2024;24:566.
     PubMed     Abstract available
     
     
     
321. SBAITY E, Tamim H, El-Hajj Fuleihan G, Abbas J, et al
     Effect of young age (below 40 years) on oncologic outcomes in Lebanese patients with breast cancer: a matched cohort study.
     BMC Cancer. 2024;24:560.
     PubMed     Abstract available
     
     
     
322. WANG J, Tian C, Zheng BJ, Zhang J, et al
     The use of longitudinal CT-based radiomics and clinicopathological features predicts the pathological complete response of metastasized axillary lymph nodes in breast cancer.
     BMC Cancer. 2024;24:549.
     PubMed     Abstract available
     
     
     April 2024
323. HAN JY, Che N, Mo J, Zhang DF, et al
     Desmoglein 2 and desmocollin 2 depletions promote malignancy through distinct mechanisms in triple-negative and luminal breast cancer.
     BMC Cancer. 2024;24:532.
     PubMed     Abstract available
     
     
     
324. ZOU J, Chen Q, He Y, Pan Y, et al
     Systematic optimization and evaluation of culture conditions for the construction of circulating tumor cell clusters using breast cancer cell lines.
     BMC Cancer. 2024;24:507.
     PubMed     Abstract available
     
     
     
325. GILL J, Yendamuri K, Chatterjee U, Yao S, et al
     Racial/ethnic differences in 21-gene recurrence score and survival among patients with estrogen receptor-positive breast cancer.
     BMC Cancer. 2024;24:461.
     PubMed     Abstract available
     
     
     
326. LIU Z, Li J, Zhao F, Ren D, et al
     Long-term survival after neoadjuvant therapy for triple-negative breast cancer under different treatment regimens: a systematic review and network meta-analysis.
     BMC Cancer. 2024;24:440.
     PubMed     Abstract available
     
     
     
327. LI B, Dai S, Wang Q, Jing H, et al
     Investigation of correlation between shear wave elastography and lymphangiogenesis in invasive breast cancer and diagnosis of axillary lymph node metastasis.
     BMC Cancer. 2024;24:409.
     PubMed     Abstract available
     
     
     
328. WU Z, Zhang Q, Jin Y, Zhang X, et al
     Population-based BRCA germline mutation screening in the Han Chinese identifies individuals at risk of BRCA mutation-related cancer: experience from a clinical diagnostic center from greater Shanghai area.
     BMC Cancer. 2024;24:411.
     PubMed     Abstract available
     
     
     
329. QIU C, Wang W, Xu S, Li Y, et al
     Construction and validation of a hypoxia-related gene signature to predict the prognosis of breast cancer.
     BMC Cancer. 2024;24:402.
     PubMed     Abstract available
     
     
     March 2024
330. ESMAT E, Haidary AM, Saadaat R, Rizvi SN, et al
     Association of hormone receptors and human epidermal growth factor receptor-2/neu expressions with clinicopathologic factors of breast carcinoma: a cross-sectional study in a tertiary care hospital, Kabul, Afghanistan.
     BMC Cancer. 2024;24:388.
     PubMed     Abstract available
     
     
     
331. ZAHEDI H, Alizadeh-Dibazari Z, Mirghafourvand M, Sahebihagh MH, et al
     The effectiveness of couple-based interventions on the marital outcomes of women with genital and breast cancer and their partners: a systematic review and meta-analysis.
     BMC Cancer. 2024;24:391.
     PubMed     Abstract available
     
     
     
332. CHEHELGERDI M, Khorramian-Ghahfarokhi M, Dehkordi FB, Chehelgerdi M, et al
     Comment on "A novel super-enhancer-related gene signature predicts prognosis and immune microenvironment for breast cancer".
     BMC Cancer. 2024;24:377.
     PubMed     Abstract available
     
     
     
333. HUANG W, Wang C, Shen Y, Chen Q, et al
     Correction: A real-world study of the effectiveness and safety of apatinib-based regimens in metastatic triple-negative breast cancer.
     BMC Cancer. 2024;24:378.
     PubMed    
     
     
     
334. REN H, Wang Z, Zhang L, Zhu G, et al
     Clinical significance of low expression of CADM3 in breast cancer and preliminary exploration of related mechanisms.
     BMC Cancer. 2024;24:367.
     PubMed     Abstract available
     
     
     
335. WANG Y, Men X, Gu Y, Wang H, et al
     Retraction Note: Haplotype analysis on correlation between transcription factor 7-like 2 gene polymorphism and breast cancer risk.
     BMC Cancer. 2024;24:366.
     PubMed    
     
     
     
336. CHANDRAN G, Tang N, Ngo ELP, Huang S, et al
     Comparing the efficacy of a multi-dimensional breast cancer rehabilitation programme versus a home-based exercise programme during adjuvant cancer treatment.
     BMC Cancer. 2024;24:361.
     PubMed     Abstract available
     
     
     
337. LOFT LH, Pedersen LH, Bigaard J, Bojesen SE, et al
     Attitudes towards risk-stratified breast cancer screening: a population-based survey among 5,001 Danish women.
     BMC Cancer. 2024;24:347.
     PubMed     Abstract available
     
     
     
338. WANG ZQ, Wu ZX, Wang ZP, Bao JX, et al
     Pan-cancer analysis of NUP155 and validation of its role in breast cancer cell proliferation, migration, and apoptosis.
     BMC Cancer. 2024;24:353.
     PubMed     Abstract available
     
     
     
339. OPUTA CH, Peters E, Otovwe A
     Effect of educational intervention on the knowledge, attitude and practice of breast self-examination among female students at a private university in Southern Nigeria.
     BMC Cancer. 2024;24:355.
     PubMed     Abstract available
     
     
     
340. BOULIFA A, Raftery MJ, Franzen AS, Radecke C, et al
     Role of beta-(1-->3)(1-->6)-D-glucan derived from yeast on natural killer (NK) cells and breast cancer cell lines in 2D and 3D cultures.
     BMC Cancer. 2024;24:339.
     PubMed     Abstract available
     
     
     
341. KNUDSEN BM, Sondergaard SR, Stacey D, Steffensen KD, et al
     Impact of timing and format of patient decision aids for breast cancer patients on their involvement in and preparedness for decision making - the IMPACTT randomised controlled trial protocol.
     BMC Cancer. 2024;24:336.
     PubMed     Abstract available
     
     
     
342. MAENPAA N, Tiainen L, Hamalainen M, Luukkaala T, et al
     Neuropilin-1 and placental growth factor as prognostic factors in metastatic breast cancer.
     BMC Cancer. 2024;24:331.
     PubMed     Abstract available
     
     
     
343. PALMER S, Blomqvist C, Holmqvist M, Lindman H, et al
     Validation of primary and outcome data quality in a Swedish population-based breast cancer quality registry.
     BMC Cancer. 2024;24:329.
     PubMed     Abstract available
     
     
     
344. KANG D, Wang C, Han Z, Zheng L, et al
     Exploration of the relationship between tumor-infiltrating lymphocyte score and histological grade in breast cancer.
     BMC Cancer. 2024;24:318.
     PubMed     Abstract available
     
     
     
345. GOH SP, Ong SC, Chan JE
     Economic evaluation of germline genetic testing for breast cancer in low- and middle-income countries: a systematic review.
     BMC Cancer. 2024;24:316.
     PubMed     Abstract available
     
     
     
346. SHITRIT IB, Wang A, Ilan K, Agassi R, et al
     Epidemiological, clinical, and pathological characteristics of invasive breast cancer in Bedouin and Jewish women in southern Israel: a retrospective comparative study.
     BMC Cancer. 2024;24:310.
     PubMed     Abstract available
     
     
     
347. KHANNA D, Sharma P, Budukh A, Vishwakarma R, et al
     Rural-urban disparity in cancer burden and care: findings from an Indian cancer registry.
     BMC Cancer. 2024;24:308.
     PubMed     Abstract available
     
     
     
348. MOLIERE S, Lodi M, Leblanc S, Gressel A, et al
     MMP-11 expression in early luminal breast cancer: associations with clinical, MRI, pathological characteristics, and disease-free survival.
     BMC Cancer. 2024;24:295.
     PubMed     Abstract available
     
     
     
349. MESHKANI Z, Moradi N, Aboutorabi A, Farabi H, et al
     A cost-benefit analysis of genetic screening test for breast cancer in Iran.
     BMC Cancer. 2024;24:279.
     PubMed     Abstract available
     
     
     
350. REN J, Chen W, Zhou Y, Sun J, et al
     The novel circRNA circ_0045881 inhibits cell proliferation and invasion by targeting mir-214-3p in triple-negative breast cancer.
     BMC Cancer. 2024;24:278.
     PubMed     Abstract available
     
     

Thank you for your interest in scientific medicine.

AMEDEO Breast Cancer is free of charge.